Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from the CLEAR study

BACKGROUND: Psoriasis can greatly impact patients’ lives by influencing clothing worn as well as by impairing sexual functioning. Secukinumab, a human monoclonal antibody selectively neutralizing interleukin‐17A, has demonstrated good efficacy and safety in the treatment of moderate‐to‐severe psoria...

Descripción completa

Detalles Bibliográficos
Autores principales: Blauvelt, A., Reich, K., Mehlis, S., Vanaclocha, F., Sofen, H., Abramovits, W., Zhao, Y., Gilloteau, I., Davenport, E., Williams, N., Guana, A., Tyring, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles and Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6084293/
https://www.ncbi.nlm.nih.gov/pubmed/28602039
http://dx.doi.org/10.1111/jdv.14391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6084293/
https://www.ncbi.nlm.nih.gov/pubmed/28602039
http://dx.doi.org/10.1111/jdv.14391

Ejemplares similares